Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells - Archive ouverte HAL Access content directly
Journal Articles European Journal of Pharmaceutics and Biopharmaceutics Year : 2020

Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells

(1) , (1) , (1) , (2) , (2) , (1) , (3) , (1)
1
2
3

Abstract

A targeted nanomedicine with humanized anti-EGFR scFv (NM-scFv) was developed for siRNA delivery into triple negative breast cancer (TNBC) cells. NM-scFv consisted of i) targeted nanovector (NV-scFv): nano-cargo with targeting properties; ii) siRNA: pharmacological agent and iii) cationic polymers (chitosan, poly-L-arginine): for siRNA complexation and endosomal escape. NV-scFv was based on superparamagnetic nanoparticle (SPION) labeled with Dylight™680, a PEG layer and a humanized anti-EGFR scFv. The PEG density was optimized from 236 ± 3 to 873 ± 4 PEGs/NV-scFv and the number of targeting ligands per NV-scFv was increased from 9 to 13. This increase presented a double benefit: i) enhanced cellular internalization by a factor of 2.0 for a 24 h incubation time and ii) few complement protein consumption reflecting a greater stealthiness (26.9 vs 45.3% of protein consumption at 150 µg of iron/mL of NHS). A design of experiments was performed to optimize the charge ratios of chitosan/siRNA (CS) and PLR/siRNA (CR) that influenced significantly: i) siRNA protection and ii) gene silencing effect. With optimal ratios (CS = 10 and CR = 10), anti-GFP siRNA was completely complexed and the transfection efficiency of NM-scFv was 69.4% vs 25.3% for non-targeted NM. These results demonstrated the promising application of our NM-scFv for the targeted siRNA delivery into TNBC cells.
Fichier principal
Vignette du fichier
S0939641120303040.pdf (1.4 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02980451 , version 1 (24-10-2022)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Phuoc Vinh Nguyen, Katel Hervé-Aubert, Stephanie David, Nolwenn Lautram, Catherine Passirani, et al.. Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, pp.74-84. ⟨10.1016/j.ejpb.2020.10.004⟩. ⟨hal-02980451⟩
53 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More